Sanofi, the French pharmaceutical giant, is set to release its third-quarter results on Friday. Let’s take a look at what you should know:
The consensus provided by the company suggests that Sanofi is expected to report net sales of €12.06 billion ($12.74 billion) for the third quarter. In the same period last year, the company reported net sales of €12.48 billion.
Business Profit Forecast
Sanofi’s quarterly business net profit, which excludes exceptional items, is forecasted to be €3.27 billion according to the company’s consensus. This compares to a business net profit of €3.61 billion in the same quarter last year.
What to Watch For
Sanofi anticipates that its business earnings per share will grow by a percentage in the mid-single-digit range at constant exchange rates by 2023. JPMorgan analysts suggest that there may be room for further upgrade in this guidance, reaching an increase in the mid-to-high single-digit range. The launch of Beyfortus, a respiratory syncytial virus treatment, is expected to contribute to this upgrade.
Aside from Beyfortus, Sanofi’s recently launched hemophilia treatment, Altuviiio, and diabetes drug, Tzield, are likely to be in focus. Jefferies analysts indicate that Dupixent, an anti-inflammatory drug, is expected to maintain its remarkable U.S. prescription growth. On the other hand, generic competition in the U.S. for Aubagio, a relapsing-multiple-sclerosis drug, and anticipated competition in Europe from the fourth quarter may result in substantial sales erosion.
Stay tuned for Sanofi’s Q3 earnings report on Friday.